 Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc NASDAQ: MRTX has appointed David Meek as Chief Executive Officer, effective immediately. Related: Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards. 